DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Tannir NM, McDermott DF, Escudier B. et al
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Journal of Clinical Oncology 2020;
38 (Suppl. 06) 609-609 , doi:10.1200/JCO.2020.38.6_suppl.609
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.